Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.
Fadi Haddad, MD
Advertisement
Fadi Haddad, MD, is an assistant professor and co-leader of the Section of Chronic Myeloid Leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Articles by Fadi Haddad, MD
Fadi Haddad, MD, discusses updates on the treatment of chronic myeloid leukemia failing frontline therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5